anti-CD137L (human), mAb (41B436)
Code | Size | Price |
---|
AG-20A-0031-C050 | 50 ug | £195.00 |
Quantity:
AG-20A-0031-C100 | 100 ug | £249.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1κ
Antibody Clonality: Monoclonal
Antibody Clone: 41B436
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Flow Cytometry
- Western Blot (WB)
Shipping:
Blue Ice
Storage:
-20°C
Images
Further Information
Alternate Names/Synonyms:
4-1BBL; TNFSF9
Concentration:
1mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. 0.2µm-filtered solution in PBS, pH 7.4. Contains no preservatives.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
Immunogen:
Recombinant human CD137L extracellular domain.
Long Description:
Monoclonal Antibody. Recognizes extracellular domain of human CD137L. Does not cross-react with mouse CD137L. Isotype: Mouse IgG1kappa. Clone: 41B436. Applications: ELISA, FACS, ICC, WB. Liquid. 0.2µm-filtered solution in PBS, pH 7.4. Contains no preservatives. The CD137 ligand (CD137L, 4-1BBL) is a member of the tumor necrosis factor (TNF) family. CD137L is a type II, transmembrane protein found on activated macrophages, dendritic cells and mature B cells. The interaction with its receptor 4-1BB induces recruitment of TNF receptor-associated factor 1 (TRAF1) and TRAF2 and interaction with the kinase p56lck. CD137 and CD137L have been reported to be involved in tumor rejection, apoptosis, anti-viral immunity, diabetes, in T and B cell co-stimulation and modulation of the immune response.
NCBI, Uniprot Number:
P41273
Package Type:
Plastic Vial
Product Description:
The CD137 ligand (CD137L, 4-1BBL) is a member of the tumor necrosis factor (TNF) family. CD137L is a type II, transmembrane protein found on activated macrophages, dendritic cells and mature B cells. The interaction with its receptor 4-1BB induces recruitment of TNF receptor-associated factor 1 (TRAF1) and TRAF2 and interaction with the kinase p56lck. CD137 and CD137L have been reported to be involved in tumor rejection, apoptosis, anti-viral immunity, diabetes, in T and B cell co-stimulation and modulation of the immune response.
Specificity:
Recognizes extracellular domain of human CD137L. Does not cross-react with mouse CD137L.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling: C. Gullo, et al.; PLoS One. 5, e10845 (2010) | Tumor necrosis factor receptor 1 associates with CD137 ligand and mediates its reverse signaling: M.C. Moh, et al.; FASEB J. 27, 2957 (2013) | Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression: W.T. Ho, et al.; Cancer Res. 73, 652 (2013)
Related Products
Product Name | Product Code | Supplier | anti-CD137L (human), mAb (ANC5D6) | ANC-365-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
anti-CD137L (human), mAb (ANC5D6) (Biotin) | ANC-365-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
anti-CD137L (human), mAb (ANC5D6) (R-PE) | ANC-365-050 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
anti-CD137L (human), mAb (ANC5D6) (preservative free) | ANC-365-820 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD137L (human)-muCD8 Fusion Protein | ANC-503-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD137L (human)-muCD8 Fusion Protein (Biotin) | ANC-503-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD137L (human)-muCD8 Fusion Protein (preservative free) | ANC-503-820 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||